<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805034</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF-CRF-2020-001</org_study_id>
    <nct_id>NCT04805034</nct_id>
  </id_info>
  <brief_title>Predictive Model for Prognosis of Chronic HBV Infection Mothers</brief_title>
  <acronym>PMFPOEPMWCHI</acronym>
  <official_title>Predictive Model for Prognosis of E Antigen-positive Mothers With Chronic HBV Infection: A Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>the Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwest Women and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baoji Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weinan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ankang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanzhong Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yan'an University Affiliated Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnancy is a complex and coordinated physiological process. Pregnancy and the postpartum&#xD;
      period are associated with unique changes in the immune system that may impact the natural&#xD;
      history of autoimmune diseases and immune-mediated infections. In the postpartum period. ALT&#xD;
      ﬂares have been reported in 20%-60% of untreated women and were more likely to occur in&#xD;
      hepatitis B e antigen (HBeAg)-positive patients. It has been postulated that postpartum ALT&#xD;
      ﬂares may arise to rapid immune restitution against hepatitis B virus (HBV) antigens in the&#xD;
      liver, when may be a timing of antiviral treatment. A large number of previous studies have&#xD;
      focused on studies on the interruption of mother-to-child transmission in women with chronic&#xD;
      hepatitis B(CHB), but studies on the prognosis of mothers undergoing pregnancy and delivery&#xD;
      are very limited. What are the factors that affect the clearance of HBeAg or HBsAg? What kind&#xD;
      of antiviral treatment protocol should be adopted for mothers with CHB? It is not only a&#xD;
      problem that needs to be solved urgently in clinical practice, but also can provide some&#xD;
      clues for understanding the occurrence and development of HBV infection in women of&#xD;
      childbearing age.&#xD;
&#xD;
      Overall, this study intends to carry out a multi-center two-way cohort study on E&#xD;
      antigen-positive CHB women in 9 hospitals in Shaanxi Province. To observe the dynamic changes&#xD;
      of virological parameters in these patients, figure out the factors of the serum HBsAg loss&#xD;
      and HBeAg seroconversion, and establish relevant predictive models.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of HBeAg loss</measure>
    <time_frame>Postpartum 96weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the rate of HBeAg seroconversion</measure>
    <time_frame>Postpartum 96weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the rate of HBsAg loss</measure>
    <time_frame>Postpartum 96weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of undetectable HBV DNA</measure>
    <time_frame>Postpartum 96weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate ALT normalization</measure>
    <time_frame>Postpartum 96weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of serum HBsAg, HBeAg, HBV DNA and HBV RNA titer</measure>
    <time_frame>at delivery, 12 weeks, 24 weeks, 48 weeks, 72 weeks, 96 weeks after delivery</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>HBeAg positive/HBsAg positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg seroconversion /HBsAg loss</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Age, BMI,Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level</intervention_name>
    <description>Exposure factors: Age, BMI, Family history, Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level</description>
    <arm_group_label>HBeAg positive/HBsAg positive</arm_group_label>
    <arm_group_label>HBeAg seroconversion /HBsAg loss</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Mothers with chronic hepatitis B infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 20-45 years old&#xD;
&#xD;
          -  Serum HBsAg positive&gt; 6 months&#xD;
&#xD;
          -  HBeAg positive at delivery&#xD;
&#xD;
          -  Good compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who give birth to stillbirth due to various reasons&#xD;
&#xD;
          -  Coinfection with HIV,HCV, syphilis or other sexually transmitted diseases&#xD;
&#xD;
          -  Severe kidney, cardiovascular, lung, nervous system or immune system diseases&#xD;
&#xD;
          -  Who are taking immunotherapy drugs or anti-tumor drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tianyan Chen, phD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tianyan Chen, phD</last_name>
    <phone>0086-18991232530</phone>
    <email>chentianyan@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naijuan Yao, phD</last_name>
    <phone>0086-13186036653</phone>
    <email>897402048@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianyan Chen</last_name>
      <phone>0086-18991232530</phone>
      <email>chentianyan@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

